MYC and kidney neoplasm: Finally, the authors found that pharmacological inhibition of Gls1 with bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl) ethyl sulfide (BPTES) abrogated the growth of MYC-driven kidney tumors (Shroff et al., 2015), implicating glutamine utilization as critical for MYC-driven RCCs, similar to what was found in MYC-driven HCC (Xiang et al., 2015).